Topiramate treatment for heavy drinkers: Moderation by a GRIK1 polymorphism

American Journal of Psychiatry

Volumn 171, Issue 4, 2014, Pages 445-452

  Kranzler, Henry R ^a   Covault, Jonathan ^b   Feinn, Richard ^c   Armeli, Stephen ^d   Tennen, Howard ^e   Arias, Albert J ^c   Gelernter, Joel ^f   Pond, Timothy ^g   Oncken, Chery ^c   Kampman, Kyle M ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d New York   (United States)

^e FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^h VA Connecticut Healthcare System ^*

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; KAINIC ACID RECEPTOR; PLACEBO; TOPIRAMATE;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOLISM; ALLELE; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADULT; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, KAINIC ACID; TREATMENT OUTCOME;

EID: 84898738608     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13081014     Document Type: Article

References (34)

1. SAMHSA: National Survey on Drug Use and Health. Washington, DC, US Department of Health and Human Services, 2013. http:// www.oas.samhsa.gov/ nsduhLatest.htm
2. Kranzler HR, Babor TF, Lauerman RJ: Problems associated with average alcohol consumption and frequency of intoxication in a medical population. Alcohol Clin Exp Res 1990; 14:119-126 (Pubitemid 20076038)
3. Cohen E, Feinn R, Arias A, Kranzler HR: Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2007; 86:214-221 (Pubitemid 44821604)
4. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R: Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003; 23:294-304 (Pubitemid 36813992)
5. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias AJ, Oncken C: Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009; 29:350-357
6. Mann K, BladströmA, Torup L, Gual A, van den Brink W: Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013; 73:706-713
7. van den Brink W, Sorensen P, Torup L, Mann K, Gaul A: Longterm efficacy, tolerability, and safety of nalmefene as-needed in alcohol dependence: a randomized, double-blind, placebocontrolled study. Alcohol Clin Exp Res 2012; 36:247A
8. Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group: A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23:1432-1442
9. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361:1677-1685 (Pubitemid 36577440)
10. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group: Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298:1641-1651
11. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J: Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32:489-497 (Pubitemid 351300992)
12. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41(suppl 1): S17-S20 (Pubitemid 30202335)
13. Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000; 41(suppl 1):S45-S47
14. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41(suppl 1):S10-S16
15. Gryder DS, Rogawski MA: Selective antagonism of GluR5 kainatereceptor- mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003; 23:7069-7074 (Pubitemid 36975871)
16. Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46:1097-1104 (Pubitemid 38529933)
17. McDonald R, Rogawski M: Cellular effects of antiepileptic drugs, in Epilepsy: A Comprehensive Textbook, 2nd ed. Edited by Engel J Jr, Pedley TA. Philadelphia, Lippincott, Williams, and Wilkins, 2006, pp 1433-1446
18. Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, Burian L, Covault J: Association of markers in the 3: region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res 2009; 33:925-930
19. Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM: A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 2009; 17:122-129
20. Pettinati H, Weiss R, Miller W, Donovan D, Ernst D, Rounsaville B: COMBINE Monograph Series, vol 2: Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of theTreatment for Alcohol Dependence (Publication number, NIH 04-5289). Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2004
21. WHO Brief Intervention Study Group: A cross-national trial of brief interventions with heavy drinkers. Am J Public Health 1996; 86:948-955
22. Sanchez-Craig M, Wilkinson DA, Davila R: Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers. Am J Public Health 1995; 85: 823-828
23. First M, Spitzer R, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY Screen). New York, New York State Psychiatric Institute, Biometrics Research,2001
24. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Publishing, 1994
25. Sobell L, Sobell M: Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption. Edited by Allen J. New York, Humana Press, 1992, pp 41-65
26. Miller W, Tonigan J: The Drinker Inventory of Consequences (DrInC), NIAAA Project MATCH Monograph Series, vol 4. Bethesda, Md, National Institutes of Health, 1995, pp 95-3911
27. Feinn R, Tennen H, Kranzler HR: Psychometric properties of the Short Index of Problems as a measure of recent alcohol-related problems. Alcohol Clin Exp Res 2003; 27:1436-1441 (Pubitemid 37151473)
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
29. Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ: Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 2010; 34:2022-2034
30. 1,000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491:56-65
31. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP, Meyer LR, Sloan CA, Malladi VS, Roskin KM, Suh BB, Hinrichs AS, Clawson H, Zweig AS, Kirkup V, Fujita PA, Rhead B, Smith KE, Pohl A, Kuhn RM, Karolchik D, Haussler D, Kent WJ: ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res 2011; 39:D871-D875
32. Breslow RA, Graubard BI: Prospective study of alcohol consumption in the United States: quantity, frequency, and causespecific mortality. Alcohol Clin Exp Res 2008; 32:513-521 (Pubitemid 351300995)
33. Dawson DA, Li TK, Grant BF: A prospective study of risk drinking: at risk for what? Drug Alcohol Depend 2008; 95:62-72
34. Jackson KM: Heavy episodic drinking: determining the predictive utility of five or more drinks. Psychol Addict Behav 2008; 22:68-77 (Pubitemid 351389759)